Can Hypertonic Saline Be Given for Acute Subdural Hematoma?
Yes, hypertonic saline can be safely administered to patients with acute subdural hematoma (SDH) to manage elevated intracranial pressure, and unlike mannitol, there is no evidence that it causes hematoma expansion. 1
Key Recommendation
The 2018 guidelines for severe traumatic brain injury management explicitly recommend using either mannitol 20% or hypertonic saline solution at a dose of 250 mOsm, infused over 15-20 minutes to treat threatened intracranial hypertension or signs of brain herniation (Grade 1+, Strong Agreement). 1 Importantly, these guidelines state that hypertonic saline "should be used instead of and not in conjunction with mannitol" for this indication. 2
The Mannitol-SDH Concern vs. Hypertonic Saline Safety
Mannitol and Hematoma Expansion
The concern about mannitol causing SDH expansion is legitimate. A 2019 study demonstrated that intraoperative mannitol administration significantly increased the risk of postoperative chronic subdural hemorrhage after unruptured aneurysm surgery (13.3% vs. 3.1%, P = 0.010). 3 Multivariate analysis confirmed mannitol administration as an independent risk factor for postoperative CSDH >50 mL (P = 0.040). 3
Hypertonic Saline Does Not Share This Risk
In contrast, hypertonic saline has been studied specifically in acute SDH without evidence of hematoma expansion. A 2008 rat model study directly investigated hypertonic/hyperoncotic treatment (7.2% saline/6% hydroxyethyl starch) in acute SDH and found that it:
- Reduced ICP effectively
- Improved cerebral perfusion pressure
- Enhanced functional and histologic outcomes
- Did not cause hematoma expansion 4
A 2022 case report documented successful prehospital use of 3% hypertonic saline in a patient with skull fracture and subdural hematoma, with seamless transition to continued infusion at the trauma center for 24 hours without complications. 5
Practical Administration Guidelines
Dosing and Concentration
- Bolus therapy: 7.5% hypertonic saline, 250 mL (most commonly studied) 2
- Continuous infusion: 3% hypertonic saline, targeting elevated sodium levels 2
- Equiosmotic dose: Approximately 250 mOsm over 15-20 minutes 1
Route of Administration
- Central line preferred but peripheral IV is safe with proper monitoring for phlebitis and extravasation 6
- Never use PVC bags with 25% mannitol (causes precipitation), but this is not an issue with hypertonic saline 7
Monitoring Requirements
- Serum sodium and chloride levels must be monitored regularly 1
- Peak sodium levels in survivors typically remain <155 mmol/L 2
- Hypernatremia and hyperchloremia are the main adverse effects (vs. osmotic diuresis with mannitol) 1
Comparative Efficacy: Hypertonic Saline vs. Mannitol
At equiosmotic doses, hypertonic saline and mannitol have comparable efficacy for reducing ICP. 1 However, hypertonic saline offers several advantages:
- Longer duration of effect: Mean difference of 0.67 hours longer than mannitol (P < 0.01) 8
- Shorter ICU stay: Significantly reduced compared to mannitol (P < 0.01) 8
- Volume expansion: Hypertonic saline provides intravascular volume support, while mannitol causes osmotic diuresis requiring volume replacement 1
- No hematoma expansion risk: Critical distinction in SDH patients 4, 3
Important Caveats
What Hypertonic Saline Does NOT Do
Despite effective ICP reduction (Grade A evidence), hypertonic saline:
- Does not improve neurological outcomes (Grade B) 2
- Does not improve survival in raised ICP states (Grade A) 2
- Prophylactic use without evidence of intracranial hypertension is not superior to crystalloids 1
Safety Profile
Multiple studies, including autopsy and MRI data, have found no evidence of osmotic demyelination syndrome even with peak sodium levels up to 170.7 mmol/L in pediatric patients (mean treatment duration 7.6 days). 2 One patient had a maximum serum osmolarity of 431 mOsm/L without adverse effects. 2
Clinical Algorithm for Acute SDH with Elevated ICP
- Confirm elevated ICP or signs of herniation (mydriasis, anisocoria, neurological deterioration)
- Control secondary brain insults first (hypoxia, hypotension)
- Administer hypertonic saline: 250 mL of 7.5% solution over 15-20 minutes OR initiate 3% infusion
- Avoid mannitol in acute SDH due to hematoma expansion risk
- Monitor sodium/chloride every 4-6 hours initially
- Expect ICP reduction within 15 minutes, lasting 2-4 hours 1
- Repeat dosing as needed based on ICP monitoring (not prophylactically)
Bottom line: Hypertonic saline is the preferred osmotic agent for acute SDH with elevated ICP, as it effectively reduces ICP without the hematoma expansion risk associated with mannitol. 1, 4, 3